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                              Women who have inherited mutations in the   BRCA1   or   BRCA2   
(  BRCA1/2  ) genes have substantially elevated risks of breast and 
ovarian cancer, with a lifetime risk of breast cancer of 56%  –  84% 
(  1    –    4  ). Breast cancer in   BRCA1/2   mutation carriers also occurs at 
an earlier age, particularly among   BRCA1   mutation carriers, 
than for noncarriers. The risk for ovarian cancer is dependent on 
whether the mutation has occurred in   BRCA1   or   BRCA2  , with 
estimated risks ranging from 36% to 46% for   BRCA1   mutation 
carriers and from 10% to 27% for   BRCA2   mutation carriers 
(  1  ,  2  ,  5    –    7  ). Carriers of   BRCA1/2   mutations are counseled to help 
them interpret the implications of these elevated risks, choose 
strategies to reduce these risks, and maximize early detection of 
cancers. The risk of breast cancer can be reduced either with 
risk-reducing oophorectomy and/or mastectomy or nonsurgi-
cally (ie, with screening and prevention techniques). However, 
due to the lack of effective screening for ovarian cancer, risk-
reducing salpingo-oophorectomy (RRSO) is usually strongly 
recommended to   BRCA1  /  2   mutation carriers once childbearing 
is complete. 
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     Background     Risk-reducing salpingo-oophorectomy (RRSO) is widely used by carriers of   BRCA1   or   BRCA2   (  BRCA1/2  ) 
mutations to reduce their risks of breast and ovarian cancer. To guide women and their clinicians in opti-
mizing cancer prevention strategies, we summarized the magnitude of the risk reductions in women with 
  BRCA1/2   mutations who have undergone RRSO compared with those who have not.   
     Methods     All reports of RRSO and breast and/or ovarian or fallopian tube cancer in   BRCA1/2   mutation carriers pub-
lished between 1999 and 2007   were obtained from a PubMed search. Hazard ratio (HR) estimates were 
identified directly from the original articles. Pooled results were computed from nonoverlapping studies 
by fixed-effects meta-analysis.   
     Results     Ten studies investigated breast or gynecologic cancer outcomes in   BRCA1/2   mutation carriers who had 
undergone RRSO. Breast cancer outcomes were investigated in three nonoverlapping studies of   BRCA1/2   
mutation carriers, four of   BRCA1   mutation carriers, and three of   BRCA2   mutation carriers. Gynecologic 
cancer outcomes were investigated in three nonoverlapping studies of   BRCA1/2   mutation carriers and one 
of   BRCA1   mutation carriers. RRSO was associated with a statistically significant reduction in risk of breast 
cancer in   BRCA1/2   mutation carriers (HR = 0.49; 95% confidence interval [CI] = 0.37 to 0.65). Similar risk 
reductions were observed in   BRCA1   mutation carriers (HR = 0.47; 95% CI = 0.35 to 0.64) and in   BRCA2   
mutation carriers (HR = 0.47; 95% CI = 0.26 to 0.84). RRSO was also associated with a statistically signifi-
cant reduction in the risk of   BRCA1/2  -associated ovarian or fallopian tube cancer (HR = 0.21; 95% CI = 0.12 
to 0.39). Data were insufficient to obtain separate estimates for ovarian or fallopian tube cancer risk reduc-
tion with RRSO in   BRCA1   or   BRCA2   mutation carriers.   
     Conclusion     The summary estimates presented here indicate that RRSO is strongly associated with reductions in the 
risk of breast, ovarian, and fallopian tube cancers and should provide guidance to women in planning 
cancer risk reduction strategies.   
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  RRSO has also been demonstrated to decrease the risk of both 
breast and ovarian cancer in   BRCA1/2   mutation carriers (  8    –    17  ). 
However, studies examining the extent of risk reduction have used 
different designs; some are retrospective case  –  control studies, whereas 
others used a prospective cohort design [reviewed by Kauff and 
Barakat   (18)]. Even among prospective studies, the inclusion criteria 
and the deﬁ  nitions of follow-up time differ. In some studies, only unaf-
fected mutation-positive women are included and followed up. In 
others, particularly when examining ovarian cancer risk, women with 
breast cancer are included. Such differences in study design can intro-
duce biases (such as survival bias) and can have an impact on risk 
reduction estimates. For example, the reported efﬁ  cacy of RRSO in 
reducing the risk of ovarian/fallopian tube cancers has varied from 
71% to 96% (  8  ,  10  ,  11  ,  13  ,  16  ,  17  ). Although these estimates imply a 
substantial reduction in risk, this variability may affect the decisions of 
premenopausal women who are making a decision about whether to 
undergo a treatment that will cause abrupt and premature menopause. 
Patients and their physicians need as much information as possible 
regarding the efﬁ  cacy of RRSO in reducing cancer risk to balance this 
beneﬁ  t with the health risks caused by premature entry into meno-
pause. Hence, we identiﬁ  ed the published studies pertaining to the 
beneﬁ  ts of RRSO in terms of reducing cancer risk, assembled informa-
tion on their design, and calculated summary risk reduction estimates 
associated with RRSO in   BRCA1/2   mutation carriers with the goal of 
aiding women and their clinicians in making cancer risk reduction 
decisions. Because randomized clinical trials of RRSO are likely not 
feasible and may not be ethically appropriate (  19  ), we report the results 
of all observational case  –  control and cohort studies in the literature. 
    Methods 
    Search Strategy 
  To identify all reports of RRSO in   BRCA1/2   mutation carriers, we 
searched the PubMed database using the search terms “oophorec-
tomy” and “BRCA1” or “BRCA2.” This search yielded 346 studies 
that were published between January 1999 and December 2007: 309 
that included the term “BRCA1” in the title and 267 that included 
the term “BRCA2” were identified. We then evaluated the full text 
of these citations to identify articles presenting primary data that 
provided estimates of risk reduction due to RRSO. No publications 
were excluded based on quality, sample size, language of publica-
tion, or other objective criteria related to study design and analysis. 
However, some publications that reported RRSO in   BRCA1/2   
mutation carriers were not included because they did not estimate 
risk reduction. These included case reports, psychosocial or behav-
ioral studies, commentaries, and clinical recommendations. Because 
the number of   BRCA1/2   mutation carriers is relatively limited and 
most research groups studying these women are in routine com-
munication and collaborate with one another, we also undertook 
personal communications with all of the researchers or consortia 
that have large series of   BRCA1/2   mutation carriers and were known 
to have data that could have been used to report data on this topic. 
This search did not reveal any additional unpublished studies.   
    Statistical Analysis 
  Data were obtained from published estimates as published in the 
original articles. We undertook a fixed-effects meta-analysis using 
the hazard ratios (HRs) and/or odds ratios (as published in the origi-
nal reports) to estimate the pooled relative risks and 95% confidence 
intervals (CIs). When two or more studies had overlapping study 
samples, we included only one published report from each group. Of 
the studies identified here, sample overlaps were noted in the studies 
of Rebbeck   et al. (8,9),  Domchek et al. (  13  ), and Kauff et al. (  16  ) and 
in those of Kauff et al. (  10,16  ). Therefore, only Kauff et al. (  16  ), 
which had the largest sample size of these five studies, was chosen 
for inclusion in the meta-analysis. There were no apparent overlaps 
among the other datasets, although we cannot rule out the possibil-
ity that a few individuals had participated in more than one study. 
  We carried out separate meta-analyses in   BRCA1   mutation 
carriers,   BRCA2   mutation carriers, and among women who 
carried either   BRCA1   or   BRCA2   mutations (denoted   BRCA1/2  ). A 
chi-square test of homogeneity among the individual risk ratio 
estimates of the identiﬁ  ed studies was also performed. To evaluate 
potential for publication bias, we used the adjusted rank correla-
tion test of Begg and Mazumdar (  20  ). All analyses were conducted 
using STATA/SE v9.0 (StatCorp, College Station, TX).     
    Results 
  The studies that formed the basis of this meta-analysis included 
case  –  control studies as well as prospective and retrospective 
cohort studies (  Table 1  ). As can be seen in this summary, limita-
tions of the currently available data regarding RRSO in   BRCA1/2   
mutation carriers include variable study designs, small sample 
sizes for individual studies, many of which are retrospective in 
    CONTEXT AND CAVEATS   
    Prior knowledge 
  Risk-reducing salpingo-oophorectomy (RRSO)  —  the removal of the 
fallopian tubes and ovaries to reduce the risks of breast and ovar-
ian cancer  —  is a cancer prevention strategy used by many women 
who carry germline mutations in the   BRCA1   and/or   BRCA2   genes 
(  BRCA1/2  ). However, the magnitude of the risk reductions in 
women with   BRCA1/2    mutations who have undergone RRSO 
compared with those who have not is unclear.   
    Study design 
  A fixed-effects meta-analysis of pooled results from 10 published 
reports of RRSO and the risks of breast and/or ovarian or fallopian 
tube cancer in   BRCA1/2   mutation carriers.   
    Contribution 
  RRSO was found to be strongly associated with substantial reduc-
tions in the risks of breast, ovarian, and fallopian tube cancers 
among women who carry mutations in   BRCA1   or   BRCA2  .   
    Implications 
  The summary risk reduction estimates should provide guidance to 
women in planning cancer risk reduction strategies.   
    Limitations 
  Data were not available to evaluate the effects of birth cohort, tim-
ing of surgery, or other factors that may influence the risk reduc-
tion estimates associated with RRSO. Women included in the 
studies were not representative of the general population. 
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nature, and short post-RRSO follow-up times in prospective 
studies. Eight studies (8-10,12-16) estimated the risk of breast 
cancer in BRCA1/2 mutation carriers who were treated with 
RRSO relative to BRCA1/2 mutation carriers who did not receive 
this treatment (Table 2). As summarized in     Table 3   and Figure 1, 
three nonoverlapping studies (  14    –    16  ), which included 5703 par-
ticipants, estimated the risk of breast cancer in   BRCA1/2   mutation 
carriers who received RRSO relative to   BRCA1/2   mutation carri-
ers who did not receive the procedure, giving a summary HR 
estimate of 0.49 (95% CI = 0.37 to 0.65). Four nonoverlapping 
studies (  12  ,  14    –    16  ) estimated the risk reduction associated with 
RRSO for breast cancer in   BRCA1   mutation carriers, giving a sum-
mary HR estimate of 0.47 (95% CI = 0.35 to 0.64). Finally, three 
nonoverlapping studies (  14    –    16  ) estimated the relative risk for 
breast cancer in   BRCA2   mutation carriers, giving a summary HR 
estimate of 0.47 (95% CI = 0.26 to 0.84) (Table 3, Figure 1).         
  Six studies (  8  ,  10  ,  11  ,  13  ,  16  ,  17  ) (  Table 2  ) estimated the risk of 
gynecologic cancer in   BRCA1/2   mutation carriers treated with 
RRSO relative to   BRCA1/2   mutation carriers who did not receive 
this treatment. Based on data from the three nonoverlapping data-
sets (  11  ,  16  ,  17  ),   which included 2840 participants, the summary 
HR was 0.21 (95% CI = 0.12 to 0.39) (Table 3, Figure 1). Only one 
study (  16  ) estimated the risk of gynecologic cancer in   BRCA1   
mutation carriers treated with RRSO relative to untreated   BRCA1   
carriers (HR = 0.15, 95% CI = 0.04 to 0.56) (Table 2). No study 
estimated the risk reduction associated with RRSO in   BRCA2   
mutation carriers. Kauff et al. (  16  ) did investigate risk reduction in 
294 women with   BRCA2   mutations, but observed no post-RRSO 
gynecologic cancers in this sample.         
  We found no evidence of publication bias of any of our esti-
mates based on the Begg and Majumder test statistics presented in 
  Table 3  . No evidence of study heterogeneity was found based on 
the    2  test (  Table 3  ).           
    Discussion 
  The clinical management of cancer risk in   BRCA1   and   BRCA2   
mutation carriers is complex and should consider patient pref-
erences; these preferences can be informed by accurate knowl-
edge of the risks and benefits of the interventions considered 
(  Table 4    ). The results of our meta-analysis suggest an 80% 
reduction in ovarian/fallopian tube cancer risk and a 50% reduc-
tion in breast cancer risk   associated with   RRSO in women who 
carry mutations in   BRCA1   or   BRCA2  . The consistency of these 
findings across the included studies confirms the strong associa-
tion of RRSO with reduced risks of breast and ovarian cancer in 
  BRCA1   or   BRCA2   mutation carriers. In addition, modeling 
studies have also demonstrated that salpingo-oophorectomy has 
a large effect on years of life added, particularly when adjusted 
for quality of life (  31  ). Furthermore, in a prospective study with 
short-term follow-up, RRSO was associated with a 90% reduc-
tion in breast cancer  –    specific mortality, a 95% reduction in 
gynecologic cancer  –  specific mortality, and a 76% reduction in 
overall mortality (  13  ). Therefore, all of the available data dem-
onstrate the utility of salpingo-oophorectomy in this population 
of patients.         
  Despite the consistent evidence favoring RRSO in women with 
mutations in   BRCA1   or   BRCA2  , the existing data remain somewhat 
  Table 1    .       Published studies of risk-reducing salpingo-oophorectomy and cancer risk in   BRCA1/2   mutation carriers  *     
    Study, first author, and year 
(reference)
Study 






Mean age at breast 
cancer (y)
Mean age at 
ovarian cancer (y)
Mean age 
at RRSO (y)      BRCA1   BRCA2   BRCA1/2     
    Rebbeck et al., 1999 (9) RC NAMC 43/79 NA 43/79 5546 PY
B1: RRSO: 44.7
NR B1: 36.8    B1: No RRSO: 43.4 
  Kauff et al., 2002 (10) PC SIS 56/48 42/24 98/72 2.0 MYFU
B1/2: RRSO: 54.5 B1/2: RRSO: 39.8
B1/2: 48.1    B1/2: No RRSO: 48.3 B1/2: No RRSO: 51.2 
  Rebbeck et al., 2002 (8) RC IMC 219/240 42/52 261/292 8.5 MYFU
B1/2: RRSO: 52.5 B1/2: RRSO: 54.9
B1/2: 42.0    B1/2: No RRSO: 50.3 B1/2: No RRSO: 50.3 
  Rutter et al., 2003 (17) CC ISMC 5/168 0/56 5/223 NA NR NR NR 
  Eisen et al., 2005 (15) CC IMC 129/2341 36/786 166/3139 NA
B1: 38.9
NR NR    B2: 40.9 
  Kramer et al., 2005 (12) PC NAMC 33/65 NR NR
16.5 MYFU, 
 11,105  PY
B1: RRSO: 47.4
NR NR    B1: No RRSO: 46.5 
  Domchek et al., 2006 (13) PC IMC 103/191 52/80 155/271 2.5 MYFU
B1/2, RRSO: 47.8 B1/2: RRSO: 44.0
B1/2: 44.8    B1/2: No RRSO: 41.7 B1/2: No RRSO: 48.3 
  Finch et al., 2006 (11) RC IMC 834/546 207/233 1041/779 3.5 MYFU NR
B1/2: RRSO: 51.1
B1/2: 46.4    B1/2: No RRSO: 53.8 
  Chang-Claude et al., 2007 (14) RC EMC NR NR 55/1601 65,675 PY B1/2: 50.1 NR NR 
  Kauff et al., 2008 (16) PC IMC 325/173 184/110 509/283 3.2 MYFU
B1: RRSO: 49.8 B1: RRSO: 46.4  
  B1: No RRSO: 44.0 B1: No RRSO: 56.2 B1: 46.2 
  B2: RRSO: 52.5 B2: RRSO: NA B2: 48.8 
  B2: No RRSO: 53.0 B2: No RRSO: 64.0    
    *     In all but one of the prospective cohort studies, women with a prior diagnosis of breast cancer were included for the ovarian endpoint. In Domchek et al. (13      ) all 
patients were unaffected with breast or ovarian cancer at the start of follow-up, as the study was designed to evaluate the impact of RRSO on cancer incidence 
as well as disease-specific and overall survival. B1 =   BRCA1   mutation carriers; B2 =   BRCA2   mutation carriers; B1/2 = combined   BRCA1     or   BRCA2   group; 
PC = prospective cohort; RC = retrospective cohort; CC = case  –  control; NAMC = North American Multicenter Cohort; SIS = single-institution study; 
IMC = International Multicenter Cohort; ISMC = Israeli Multicenter Cohort; EMC = European Multicenter Cohort; MYFU = mean years of follow-up; 
PY = person-years; NR = not reported; and NA = not applicable; RRSO = risk-reducing salpingo-oophorectomy.   
      †       In the original publications, the prospective and retrospective cohorts were analyzed by survival/failure time analysis methods; the case  –  control studies were 
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limited in a number of ways. First, the inﬂ  uence of cohort effects 
on cancer risk over time remain unclear, despite evidence that dif-
ferences in risk over time may reﬂ  ect changing exposures, lifestyle, 
reproductive history, and use of screening or preventive surgeries 
(  32  ). We lacked the data necessary to evaluate the effects of birth 
cohort, timing of surgery, or other factors that may inﬂ  uence the 
risk reduction estimates associated with RRSO. Therefore, at this 
time it is difﬁ   cult to infer whether speciﬁ   c cohorts, exposure 
groups, or other strata may experience different risk reduction 
effects than others. 
  To limit the possibility that reporting bias inﬂ  uenced  our 
ﬁ  ndings, we included all published studies of RRSO in   BRCA1/2   
  Table 2    .       Published studies of risk-reducing salpingo-oophorectomy and cancer risk in   BRCA1/2   mutation carriers  *     
    Study, first author, and 
year (reference)
Ovarian and/or fallopian tube cancer by 
mutation status Breast cancer by mutation status 
    BRCA1/2   BRCA1   BRCA2   BRCA1/2   BRCA1   BRCA2     
    Rebbeck et al., 1999 (9) NA NA NA NA HR = 0.53 
  (0.33 to 0.84), 
  N = 122    †   
NA 
  Kauff et al., 2002 (10) HR = 0.15 
  (0.02 to 1.31), 
  N = 170    †   
NA NA HR = 0.32 
  (0.08 to 1.20), 
  N = 131    †   
NA NA 
  Rebbeck et al., 2002 (8) HR = 0.04 
  (0.01 to 0.16), 
  N = 551    †   
NA NA HR = 0.47 
  (0.29 to 0.77), 
  N = 241    †   
NA NA 
  Rutter et al., 2003 (17) OR = 0.29 
  (0.12 to 0.73), 
  N = 251
NA NA NA NA NA 
  Eisen et al., 2005 (15) NA NA NA OR = 0.46 
  (0.32 to 0.65), 
  N = 3305
OR = 0.44 
  (0.29 to 0.66), 
  N = 2432
OR = 0.57 
  (0.28 to 1.15), 
  N = 873 
  Kramer et al., 2005 (12) NA NA NA NA HR = 0.38 
  (0.15 to 0.97), 
  N = 98
NA 
  Domchek et al., 2006 (13) HR = 0.11 
  (0.03 to 0.47), 
  N = 426    †   
NA NA HR = 0.36 
  (0.20 to 0.67), 
  N = 426    †   
NA NA 
  Finch et al., 2006 (11) HR = 0.20 
  (0.07 to 0.58), 
  N = 1828
NA NA NA NA NA 
  Chang-Claude et al., 2007 (14) NA NA NA HR = 0.56 
  (0.29 to 1.09), 
  N = 1601
HR = 0.50 
  (0.24 to 1.04), 
  N = 1187
HR = 0.40 
  (0.07 to 2.44), 
  N = 414 
  Kauff et al., 2008 (16) HR = 0.12 
  (0.03 to 0.41), 
  N = 792
HR = 0.15 
  (0.04 to 0.56), 
  N = 498
HR = 0.00,    ‡     
  N = 294
HR = 0.53 
  (0.29 to 0.96), 
  N = 597
HR = 0.61 
  (0.30 to 1.22), 
  N = 368
HR = 0.28 
  (0.08 to 0.92), 
  N = 229   
    *     Hazard ratios (HRs), odds ratios (ORs) (with 95% confidence intervals), and sample size (N) are presented. All   P   values are two-sided. NA = not applicable.   
      †       Not included in summary HR estimate because the sample set overlaps with that of other reports. Studies included in the summary estimate were chosen to 
maximize the sample size (power) of the meta-analysis.   
      ‡       No postsurgery events were observed; 95% CI could not be estimated.     
  Table 3    .       Summary estimates for ovarian/fallopian tube cancer and breast cancer risk reduction associated with salpingo-oophorectomy 
in   BRCA1/2   mutation carriers  *     
    Summary characteristic
Ovarian and/or fallopian tube cancer by 
mutation status Breast cancer by mutation status 
    BRCA1/2   BRCA1   BRCA2   BRCA1/2   BRCA1   BRCA2     
    Studies included (11,16,17) NA NA (14  –  16) (12,14  –  16) (14  –  16) 
  HR (95% CI) 0.21 (0.12 to 0.39) NA NA 0.49 (0.37 to 0.65) 0.47 (0.35 to 0.64) 0.47 (0.26 to 0.84) 
    P   value for heterogeneity 
 among  studies    †   
.999 NA NA .998 1.000 .604 
    P   value for publication bias    ‡   .999 NA NA .602 .176 .602   
    *     NA = not applicable; HR = hazard ratio; CI = confidence interval.   
      †       Derived from       
2   test.   
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mutation carriers. However, we did not include any studies that 
reported the association of RRSO with cancer risk without provid-
ing estimates of risk reduction because these data would not con-
tribute to pooled estimates of risk reduction. Because some studies 
included in the this analysis were limited in sample size and statis-
tical power, their effect estimates for RRSO were large but not 
statistically signiﬁ   cant, suggesting that a meta-analysis and 
presentation of summary statistics was appropriate. Two studies 
(  15  ,  17  ) were included in the summary estimates even though they 
used case  –  control designs, and therefore   they yielded odds ratios 
  Table 4    .       Synopsis of management strategies available to   BRCA1   and   BRCA2   mutation carriers  *     
    Management option Strategy Advantage Limitation   
    Gynecologic cancer     
         Chemoprevention Oral contraceptive pills Likely 30%  –  60% reduction in 
  ovarian cancer risk (21,22)
Potential increase risk of breast 
 cancer  (23,24) 
         Screening Transvaginal ultrasound, serum 
 CA-125
Avoids RRSO Unproven efficacy (25) 
         Risk-reducing surgery Bilateral salpingo-oophorectomy Substantial decrease in risks of 
  ovarian and fallopian tube 
  cancers (this study)
Premature menopause and 
 iatrogenic  infertility 
  Breast cancer     
         Chemoprevention Selective estrogen receptor 
  modulators (tamoxifen, raloxifene)
May reduce risk of ER-positive 
  breast cancer (26,27)
Very limited data in   BRCA1/2   
 mutation  carriers 
         Screening Yearly MRI
  ≈  80% sensitive for detection of 
 malignancy  (28,29)
Issues of specificity (false positives) 
  Yearly mammogram
Does not prevent cancer, goal is 
 early  detection 
  Self breast examination, clinical 
 breast  examination 
         Risk-reducing surgery Bilateral salpingo-oophorectomy Substantial decrease in breast 
  cancer risk (this study)
Premature menopause, iatrogenic 
 infertility 
  Mastectomy, with or without breast 
 reconstruction
Highly effective (30) Body image and quality-of-life 
 issues   
    *     RRSO = risk-reducing salpingo-oophorectomy; ER = estrogen receptor; MRI = magnetic resonance imaging.     
  Figure 1    .         Forest plots of relative risk (RR) estimates for risk reduction 
associated with risk-reducing salpingo-oophorectomy (RRSO).   A  ) 
Ovarian cancer risk reduction in   BRCA1/2   mutation carriers.   B  ) Breast 
cancer risk reduction in   BRCA1/2   mutation carriers.   C  ) Breast cancer 
risk reduction in   BRCA1   mutation carriers.   D  ) Breast cancer risk 
reduction in   BRCA2   mutation carriers. The   box   sizes reﬂ  ect the rela-
tive sample sizes of the individual studies;   horizontal lines   represent 
95% conﬁ  dence intervals (CIs).   Diamonds   represent the pooled point 
estimate and 95% conﬁ  dence intervals.   Vertical dashed lines   repre-
sent the pooled relative risk estimate. Estimates less than a value of 
1.0 suggest a favorable reduction in cancer risk associated with 
RRSO.       
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rather than hazard ratios. Although odds ratios may slightly over-
estimate the risk reduction associated with RRSO, the annual 
incidence of ovarian and breast cancer in   BRCA1/2   mutation car-
riers is no more than 2%  –  4%, with the result that odds ratios are 
likely to be similar to hazard ratios in this setting. 
  Some of the variability in the individual study estimates 
reported may reﬂ  ect study design differences, including the use of 
retrospective vs prospective samples and poorly characterized 
selection biases. Despite these differences, we noted no statisti-
cally signiﬁ  cant heterogeneity in the estimates of risk reduction 
after RRSO. In addition, cohort studies estimated a greater reduc-
tion in cancer risk associated with RRSO (particularly ovarian/
fallopian tube cancers) compared with the case  –  control studies 
(  Table 1  ). As a result, there is some variability in the estimates 
obtained using case  –  control and cohort studies; nonetheless, the 
estimates all consistently reﬂ   ect risk reduction associated with 
RRSO. 
  We have included all of the large collaborative group studies 
that addressed the question of reduced risk conferred by RRSO 
and whose study populations come from and are representative of 
mutation carriers in North America and Europe. No studies of 
RRSO in nonwhite populations have been reported, and additional 
data may be needed to understand the role of RRSO in these 
groups. Finally, the samples of women with   BRCA1/2   mutations 
reported here represent those who have generally been identiﬁ  ed 
through high-risk clinics. Thus, these women may not be repre-
sentative of the general population. However, they do represent 
the population of women who receive genetic testing and may be 
candidates for RRSO. Therefore, the populations summarized 
here represent the most relevant group in whom RRSO may be 
applied at this time. 
  Despite the strength and consistency of the data in the litera-
ture as reﬂ   ected in our meta-analysis, a number of questions 
remain. There are only a few estimates of the association of RRSO 
with cancer risk in populations composed exclusively of   BRCA1   
mutation carriers or   BRCA2   mutation carriers (  12  ,  14    –    16  ), and it is 
critical to understand how risk reduction may differ by gene. Using 
a prospective cohort approach and a large consortium dataset, we 
recently estimated gene-speciﬁ  c risks and found that hormonal 
modulation by RRSO may be associated with a greater reduction 
in breast cancer risk in   BRCA2   mutation carriers than in   BRCA1   
mutation carriers (  16  ). In contrast, the studies that used retrospec-
tive cohort (  14  ) or case  –  control approaches (  14  ,  15  ) did not observe 
this difference, and therefore, there was no difference in the pooled 
estimates of breast cancer risk reduction reported in   Table 1  . 
Thus, differences in study design may inﬂ  uence the inferences we 
can make about the differences in risk reduction associated with 
RRSO in   BRCA1   vs   BRCA2   mutation carriers. The potentially 
larger risk reduction associated with RRSO in   BRCA2   vs   BRCA1   
mutation carriers is of interest, given the high proportion of estro-
gen receptor (ER)  –  negative breast tumors in   BRCA1   mutation 
carriers compared with   BRCA2   mutation carriers (  33  ). Our obser-
vation of a higher risk in   BRCA2   mutation carriers should be fol-
lowed up in larger studies that speciﬁ  cally evaluate tumor markers. 
In addition, attention needs to be given to the time interval 
between RRSO and breast cancer diagnosis. For example, it is pos-
sible that there is greater breast cancer risk reduction in   BRCA2   
mutation carriers, in whom the majority of tumors are ER positive, 
given that RRSO may treat some subclinical breast tumors. In 
contrast, in   BRCA1   mutation carriers, who have predominantly 
ER-negative breast cancer, it is unclear whether a “treatment 
effect” may exist, and any primary prevention effect may require 
more time to emerge. 
  Finally, the effect of age at RRSO on cancer risk reduction 
remains unresolved. Eisen et al. (  15  ) reported that the breast can-
cer risk reduction with RRSO was greater in   BRCA1/2   mutation 
carriers who underwent surgery before age 50 than in women who 
underwent surgery after age 50. Among   BRCA1   mutation carriers 
older than age 50, no risk reduction was evident with RRSO. No 
statistically signiﬁ  cant association of RRSO at any age with risk 
reduction was observed in   BRCA2   mutation carriers. Although 
these ﬁ  ndings are consistent with effects of removal of hormone 
exposures in premenopausal women and not in postmenopausal 
women, the sample sizes in this analysis (  15  ) were relatively small. 
Thus, additional studies are required to resolve the optimal age at 
surgery. 
  The importance of understanding the optimal age at which a 
woman should consider RRSO is underscored by a recent study 
(  34  ) conducted in the general population that suggests that RRSO 
in women younger than age 45 is associated with an increased 
mortality, particularly if hormone replacement therapy (HRT) is 
not used. An initial report of HRT use after RRSO suggests that 
women can undergo RRSO and take HRT for a short time if 
needed after surgery because breast cancer risk is not substantially 
elevated in HRT users after RRSO (  35  ). Although data on post-
menopausal women do not demonstrate a cardiovascular beneﬁ  t 
from HRT (  36  ), an important limitation of   this study (  36  )   was the 
older age of the participants. More recent data have suggested that 
younger women going through natural menopause may indeed 
derive a cardiovascular beneﬁ  t from HRT (  36  ,  37  ), and it is possible 
that   BRCA1/2   mutation carriers undergoing abrupt surgical meno-
pause to reduce ovarian cancer risk who receive HRT may in fact 
derive important cardiovascular, bone health, and quality-of-life 
beneﬁ  ts. Although the risk  –  beneﬁ  t ratio of RRSO is very different 
in   BRCA1/2   mutation carriers than in the general population, and 
RRSO in   BRCA1/2   mutation carriers has been associated with 
improved overall survival in the short term, these studies pointing 
to the potentially complex relationship of RRSO and HRT expo-
sure raise important and difﬁ  cult questions. For example, it is not 
yet clear whether the long-term effects of long-term HRT in unaf-
fected mutation   BRCA1/2   carriers will ultimately be more beneﬁ  -
cial in preventing noncancer mortality in these women or more 
harmful by increasing their risk of breast cancer (or potentially 
increasing cardiovascular events) compared with the general popu-
lation. Given this possibility, studies that address the type, timing, 
and length of administration of HRT as well as its long-term 
effects on the association between RRSO and cancer risk and on 
other health factors in   BRCA1/2   mutation carriers are urgently 
needed. In the interim, we provide a summary of clinical recom-
mendations related to the detection and prevention of cancer in 
  BRCA1/2   mutation carriers (  Table 4  ). 
  Finally, although RRSO has become the standard of care for 
cancer risk reduction in women who have inherited   BRCA1/2   
mutations, other options for risk reduction also exist. Women with 86   Articles | JNCI  Vol. 101, Issue 2  |  January 21, 2009
  BRCA1/2   mutations who have been treated with risk-reducing mas-
tectomy have a substantially reduced breast cancer risk (  30  ). 
Furthermore, a study of breast cancer screening that added yearly 
magnetic resonance imaging to screening mammography suggested 
that combination of these modalities may also have beneﬁ  t in the 
early detection of breast cancer in this group of women (  28  ). 
  In conclusion, the summary risk reduction estimates presented 
here conﬁ   rm that   BRCA1/2   mutation carriers who have been 
treated with RRSO have a substantially reduced risk of both breast 
and ovarian cancer. However, residual cancer risk remains after 
surgery. Therefore, additional cancer risk reduction and screening 
strategies are required to maximally reduce cancer incidence and 
mortality in this high-risk population.         
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